Will FDA advisers recommend a multi-cancer blood test for approval? They'll vote
FDA cancer test vote
Covered by 6 sources
- Inc Magazine·7h agoThis Controversial Cancer Test Just Passed a Key FDA Vote. Here’s Why It’s Dividing Experts
Grail’s Galleri test costs $1,000 and promises comprehensive early-stage screening for more than 50 types of cancer.
Read at Inc Magazine → - Washington Post US·19h agoOne blood test could screen you for 50 cancers. Here’s why it’s controversial.
A Food and Drug Administration committee backed a cancer blood test called Galleri but was split on how well it works. The test is awaiting a final decision by the FDA.
Read at Washington Post US → - Scientific American·1d agoBlood test for multiple cancers clears crucial hurdle on track to FDA approval
If approved, the test could help catch cancers early—but more research is still needed, experts say
Read at Scientific American → - Forbes Business·1d agoGalleri, The Blood Test That Can Detect Cancers, Is Up For FDA Approval Today
Multi-Cancer Early Detection (MCED) testing is a rapidly growing field.
Read at Forbes Business → - Medical Xpress·1d agoGrail's cancer blood test faces high-stakes FDA review
A blood test designed to spot signs of multiple cancers in apparently healthy people faces its first major regulatory hurdle Wednesday as advisers to the U.S. government review how well it works.
Read at Medical Xpress → - NPR News Now·1d agoWill FDA advisers recommend a multi-cancer blood test for approval? They'll vote
The company Grail says its Galleri blood test can detect up to 50 forms of cancer. An independent panel of experts will decide if the test should be recommended for FDA approval.
Read at NPR News Now →